New trial of Genmab substance is symptomatic of Deborah Dunsire's Lundbeck

The study involving the Lu AF82422 antibody illustrates several of Lundbeck's recent tendencies, including attempts to ensure a higher study success rate and more substances in the company pipeline. This goes for both the approach to development and the variety of substances.

Since Deborah Dunsire joined Lunbeck three years ago, she has been hard at work getting the success rate of the company's research and development efforts back on track. | Photo: Gregers Tycho/ERH

BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

Published: 10.11.21 at 14:20

The newly announced phase II trial with the substance Lu AF82422, which is part of a collaboration between Genmab and Lundbeck, is in many ways an example of the new research strategy that Lundbeck has created under the leadership of CEO Deborah Dunsire and Head of Research and Development Johan Luthman.

Instead of targeting the common and easily recognizable Parkinson's disease, the drug was tested in a phase I study against the parkinsonism known as multiple system atrophy (MSA), which is a neurodegenerative disorder related to Parkinson's disease.

Already a subscriber? Log in.